Published • loading... • Updated
Hair Loss Jabs Teased by Wegovy Makers
Novo sees hair loss as a faster consumer-facing opportunity as it looks to diversify beyond Ozempic and Wegovy, which face patent expiry.
Summary by PerthNow
4 Articles
4 Articles
The Ozempic and Wegovy manufacturer is looking for new growth areas beyond diabetes and obesity. The treatment of hair loss is also in focus – a market in which Novo Nordisk could use both its hormone expertise and direct distribution to patients.
·Vienna, Austria
Read Full Article
Absci surges 9.06% to $10.71 as Novo Nordisk eyes hair-loss market
Absci (ABSI) stock surged 9.06% on September 22, closing at $10.71 . The jump followed news that Novo Nordisk is targeting the hair-loss market as part of its post-Wegovy strategy. The daily chart now shows Absci firmly in bullish territory, though shorter-term signals suggest the rally may pause....
Coverage Details
Total News Sources4
Leaning Left0Leaning Right2Center1Last UpdatedBias Distribution67% Right
Bias Distribution
- 67% of the sources lean Right
67% Right
C 33%
R 67%
Factuality
To view factuality data please Upgrade to Premium
